Literature DB >> 15213172

Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies.

Oscar Zaragoza1, Arturo Casadevall.   

Abstract

Murine cryptocococcal pulmonary infection elicited serum immunoglobulin M (IgM) and IgG to the capsular polysaccharide, but only IgG stained yeast cells in alveoli. Both isotypes produced punctuate immunofluorescence patterns on yeast cells like those of nonprotective antibodies. The difficulties involved in associating humoral immunity with protection in murine cryptocococcal infection could reflect nonprotective antibody responses.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15213172      PMCID： PMC427406          DOI： 10.1128/IAI.72.7.4271-4274.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  35 in total

1.  Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.

Authors:  T C MacGill; R S MacGill; A Casadevall; T R Kozel
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

2.  Monoclonal antibody mediated capsular reactions (Quellung) in Cryptococcus neoformans.

Authors:  J Mukherjee; W Cleare; A Casadevall
Journal:  J Immunol Methods       Date:  1995-07-17       Impact factor: 2.303

3.  Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.

Authors:  M Feldmesser; A Casadevall
Journal:  J Immunol       Date:  1997-01-15       Impact factor: 5.422

4.  The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.

Authors:  W Cleare; A Casadevall
Journal:  Clin Diagn Lab Immunol       Date:  1998-03

5.  Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.

Authors:  A Casadevall; W Cleare; M Feldmesser; A Glatman-Freedman; D L Goldman; T R Kozel; N Lendvai; J Mukherjee; L A Pirofski; J Rivera; A L Rosas; M D Scharff; P Valadon; K Westin; Z Zhong
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

6.  A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis.

Authors:  R Fleuridor; Z Zhong; L Pirofski
Journal:  J Infect Dis       Date:  1998-10       Impact factor: 5.226

7.  Monoclonal antibodies reveal additional epitopes of serotype D Cryptococcus neoformans capsular glucuronoxylomannan that elicit protective antibodies.

Authors:  J Mukherjee; T R Kozel; A Casadevall
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

8.  Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV- individuals.

Authors:  M Deshaw; L A Pirofski
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

9.  Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.

Authors:  G Nussbaum; W Cleare; A Casadevall; M D Scharff; P Valadon
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

10.  Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization.

Authors:  J Mukherjee; A Casadevall; M D Scharff
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307
View more
  8 in total

1.  The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response.

Authors:  Oscar Zaragoza; Mauricio Alvarez; Andrew Telzak; Johanna Rivera; Arturo Casadevall
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

2.  Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

3.  Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cells.

Authors:  Johanna Rivera; Oscar Zaragoza; Arturo Casadevall
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

4.  Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity.

Authors:  Ashraf S Ibrahim; Brad J Spellberg; Valentina Avenissian; Yue Fu; Scott G Filler; John E Edwards
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

5.  Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans.

Authors:  Diane C McFadden; Bettina C Fries; Fang Wang; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2007-06-29

6.  Vaccines for invasive fungal infections.

Authors:  Brad Spellberg
Journal:  F1000 Med Rep       Date:  2011-07-01

7.  The role of Aspartyl aminopeptidase (Ape4) in Cryptococcus neoformans virulence and authophagy.

Authors:  Fabiano de Assis Gontijo; Amanda Teixeira de Melo; Renata C Pascon; Larissa Fernandes; Hugo Costa Paes; J Andrew Alspaugh; Marcelo A Vallim
Journal:  PLoS One       Date:  2017-05-25       Impact factor: 3.240

Review 8.  The capsule of Cryptococcus neoformans.

Authors:  Arturo Casadevall; Carolina Coelho; Radames J B Cordero; Quigly Dragotakes; Eric Jung; Raghav Vij; Maggie P Wear
Journal:  Virulence       Date:  2018-08-01       Impact factor: 5.882
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.